In this episode we discuss:
-
Sandra’s background
-
Overview of Debiopharm
-
Tell me a bit about Debiopharm’s approach to drug development. How does it work with startups to enhance innovation and expedite clinical trial timelines?
-
What steps can companies take to improve patient quality of life in drug development?
-
As the world continues to face a global drug shortage, how does Debiopharm bridge the gap between disruptive research and real-world application to ensure patients receive the life-saving drugs they need?
-
What’s next for the future of biopharma?
Watch
Listen
Read
Bridging the Gap Between Biotech and Pharma
Sandra von Meier begins by discussing her background in the biotech and pharma industry, highlighting her experience in oncology and her passion for in-licensing and out-licensing partnerships. She shares how her path led her to Debiopharm, a company uniquely positioned between biotech and pharma, acting as a catalyst for the next level of development. The focus on oncology and the ability to bring innovative assets to market make Debiopharm’s business model truly exceptional.
Enhancing Innovation and Expediting Clinical Trials
Sandra explains Debiopharm’s approach to drug development, emphasizing their expertise in clinical and preclinical development, as well as manufacturing. Debiopharm collaborates with early-stage biotech companies, adding value to their products and preparing them for clinical trials. They also seek out pharma partners for out-licensing, ensuring these promising assets reach the patients who need them most. By funding and supporting these programs, Debiopharm plays a crucial role in enhancing innovation and expediting clinical trial timelines.
Improving Patient Quality of Life
Patient quality of life is a central focus for Debiopharm. Sandra sheds light on the challenges faced by patients with severe diseases and the limited treatment options available. Debiopharm is committed to addressing these gaps, developing novel treatments for diseases like glioblastoma and novel antibiotics to combat drug resistance. By investing in disruptive science and manufacturing capabilities, Debiopharm ensures essential products reach patients and supports the worldwide supply chain, even during times of drug shortages.
The Future of Biopharma
Looking ahead, Sandra discusses the future of biopharma and the areas of development that Debiopharm is exploring. She highlights the potential of cancer vaccines, leveraging the success of mRNA vaccine development, and enhancing the immune response against cancer. She also mentions the role of AI in selecting the right patients for clinical trials, optimizing outcomes, and reducing complications. Debiopharm’s investment in AI technology and its commitment to disruptive science position them at the forefront of the evolving biopharma landscape.
WORD FROM OUR SPONSORS:
Our sponsor for this episode are Sage Growth Partners.
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media – @sagegrowthpartners
Learn more about Debiopharm follow these links:
– LinkedIn – Website –
Also, be sure to follow Slice of Healthcare on our social channels:
– Website – LinkedIn – Twitter – YouTube – Newsletter –
